Q-omics provides the consensus-scored FDXACB1 profile across patient tissues and cancer cell-line models. FDXACB1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, FDXACB1 is differentially expressed in 15, with the highest sampling consensus in STAD. Additionally, FDXACB1 RNA expression shows 18,542 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and STAD as cancer lineages where FDXACB1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FDXACB1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FDXACB1 survival associations across molecular data types. FDXACB1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FDXACB1 RNA expression–survival associations across cancer types. High FDXACB1 expression shows unfavorable associations in UVM and ACC, but favorable associations in LUAD, READ, UCEC and BRCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for FDXACB1 RNA expression.
This table summarizes FDXACB1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for FDXACB1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FDXACB1 shows lower tumor expression in THCA and KICH and higher tumor expression in STAD, LIHC, BRCA and HNSC. The STAD box plot shows higher FDXACB1 RNA expression in tumor versus normal tissue (log2 FC = +0.597, t-test p < 0.001).
This table shows molecular features associated with FDXACB1 in patient tissues and cancer cell lines. In patient samples, FDXACB1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, FDXACB1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
